(Novavax) Britain’s Medicines and Healthcare products Regulatory Agency has approved Novavax Inc.’s protein-based vaccine NVX-CoV2373.
The vaccine would be the first protein-based for active inoculation against Covid-19 caused by SARS-CoV-2 for individuals above 18 years.
The approval was based on a review of studies conducted on almost 15,000 UK participants in the ongoing Phase 3 trials.
Novavax’s CEO and president Stanley C. Erck lauded the authorization, saying it would help the UK tackle its next phase of the Covid-19 pandemic.
The UK already has an agreement to supply up to 60 million doses of the Novavax vaccine.
NVAX: NASDAQ is currently down -0.18% on premarket.
